Clinical trials: Leukemia Acute Myeloid
Acute Myeloid Leukemia (AML)
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
This is a clinical study on the use of iNK cells for the treatment of refractory relapsed acute myeloid leukemia.
- Trial name
- iNK-r/r AML (NCT06702098)
- Testing
- iNK cells
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Guangzhou Ruixin Biotechnological Co., LTD
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
The purpose of this study is to determine whether addition of AS101 to the standard chemotherapy regimen is effective in the treatment of newly diagnosed elderly (≥60) AML patients and AML transformed myelodysplastic syndrome…
- Trial name
- NCT01010373
- Testing
- AS101
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- BioMAS Ltd
Acute Myeloid Leukemia
Study of GDX012 in Patients With MRD Positive AML
The purpose of this first-in-human study is to assess the safety, tolerability, antileukemic activity and maximum tolerated dose (MTD) of GDX012 in AML patients who are MRD positive by multiparametric flow cytometry.
- Trial name
- NCT05001451
- Testing
- GDX012 Suspension for IV Infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- GammaDelta Therapeutics Limited
Relapsed or Refractory Acute Myeloid Leukemia
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
The primary objective of this study is to evaluate the safety and tolerability of AMG 330, administered in combination with pembrolizumab, in participants with relapsed or refractory acute myeloid leukemia (R/R AML).
- Trial name
- NCT04478695
- Testing
- AMG 330, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Amgen
Leukemia
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to determine the safety and effectiveness of ulocuplumab in combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid Leukemia (AML).
- Trial name
- NCT02305563
- Testing
- BMS-936564, Cytarabine
- Where
- 38 sites in United States, Brazil and 8 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukaemia
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
This is a single group, Phase 1, single-arm, dose escalation study to determine the candidate dose(s), and evaluate safety, tolerability, and preliminary anti-tumor activity of SAR445419 administered after fludarabine and…
- Trial name
- NCT05712278
- Testing
- SAR445419, fludarabine, cytarabine
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sanofi
Acute Myeloid Leukemia (AML)
A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid…
- Trial name
- NCT07623616
- Testing
- ziftomenib
- Where
- 20 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Acute Myelogenous Leukemia
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)
This is a phase I, single-arm, open-label, multi-center study of rising doses of Troxatyl™ whose purpose is to determine the safety, tolerance, and pharmacokinetics, and to establish the recommended infusion schedule of Troxatyl™.
- Trial name
- NCT00104468
- Testing
- Troxatyl™ (Cytotoxic Chemotherapeutic)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- SGX Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
- Trial name
- NCT02626338
- Testing
- Crenolanib, Mitoxantrone, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Arog Pharmaceuticals, Inc.
AML, Adult, MDS
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who…
- Conditions
- AML, Adult, MDS, Relapse/Recurrence, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04749355
- Testing
- BST-236
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- BioSight Ltd.
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Non-randomized, open, dose ranging and dose scheduling study of ascending doses of KW-2449 in subjects with AML, ALL, MDS and CML.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
- Trial name
- NCT00346632
- Testing
- KW-2449
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Kyowa Kirin, Inc.
R/R AML, R/R HR-MDS
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
The drug that will be investigated in the trial is an antibody, GEN3018. Since this is the first trial of GEN3018 in humans, the main purpose is to evaluate safety.
- Conditions
- R/R AML, R/R HR-MDS, Acute Myeloid Leukemia, Higher-Risk Myelodysplastic Syndrome
- Trial name
- NCT07384715
- Testing
- GEN3018
- Where
- 9 sites in Denmark, Italy and 1 more
- Volunteers
- 78 people
- Sponsor
- Genmab
Relapsed/Refractory AML
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese…
- Trial name
- NCT04839341
- Testing
- Uproleselan
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Apollomics Inc.
Leukemia, Myeloid, Chronic, Myeloid Leukemia
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase…
- Conditions
- Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT04260022
- Testing
- Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab
- Where
- 9 sites in United States, Canada
- Volunteers
- 242 people
- Sponsor
- Ascentage Pharma Group Inc.
Acute Myeloid Leukemia
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
Acute myeloid leukemia (AML), also referred to as acute myelogenous leukemia or acute non-lymphocytic leukemia, is a relatively rare, yet aggressive, type of cancer.
- Trial name
- NCT06362031
- Sponsor
- AbbVie
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Chronic Myelogenous Leukemia
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
This study is composed of Phase I and Phase II part. Phase I part: The objective is to evaluate the safety of BMS-354825 in subject with chronic phase Chronic Myelogenous Leukemia (CML).
- Trial name
- NCT00337454
- Testing
- Dasatinib
- Where
- 21 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma
Long-Term Follow-up Study
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT.
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- LTFS (NCT05332054)
- Testing
- Caribou-sponsored investigational therapy
- Where
- 31 sites in United States
- Volunteers
- 150 people
- Sponsor
- Caribou Biosciences, Inc.
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Pevonedistat is a medicine to treat people with blood cancers or solid tumors. The main aim of the study is to learn about the levels of pevonedistat in the blood of participants with blood cancers or solid tumors, who also have…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency
- Trial name
- NCT03814005
- Testing
- Azacitidine, Pevonedistat
- Where
- 8 sites in United States, Spain
- Volunteers
- 17 people
- Sponsor
- Takeda
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.
- Conditions
- Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT03263637
- Testing
- AZD4573
- Where
- 12 sites in Germany, Netherlands and 1 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.